Researchers at Princeton's Ludwig Institute for Cancer Research have uncovered how retinoic acid, a metabolite of vitamin A, secretly undermines the body's anti-cancer defenses. The findings resolve a decades-old scientific paradox and point to a promising new treatment approach.

The team found that cancer cells overproduce retinoic acid not to benefit themselves, but to sabotage nearby immune cells. The compound reprograms dendritic cells—the immune system's alarm system—to tolerate tumors rather than attack them. This explains why high vitamin A intake correlates with increased cancer risk despite the nutrient's apparent anti-cancer properties in lab studies.

To counter this effect, the researchers developed KyA33, an experimental drug that blocks retinoic acid production. In animal studies, the inhibitor dramatically improved cancer vaccine effectiveness and slowed tumor growth when used alone. The team has launched biotech company Kayothera to bring ALDH1A inhibitors to clinical trials for cancer, diabetes, and cardiovascular disease.